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Innate lymphoid cells (ILCs) are novel players in innate immunity. Tumanov et al. (Tumanov et al., 2011)
demonstrate that crosstalk between ILCs and dendritic cells involving membrane-bound lymphotoxin in
ILCs and its receptor is critical for protection against colitogenic bacteria.The innate immune system is composed
of a large collection of cells, including
many myeloid subtypes, such as mono-
cytes/macrophages, a variety of polymor-
phonuclear cells, including neutrophils,
basophils, mast cells, and eosinophils,
and several lymphocyte populations.
These innate cells have in common that
they promptly react to foreign insults by
making a great variety of effector mole-
cules that provide immediate protection
against pathogenic microorganisms. At
the same time, some of these innate cells
recruit adaptive immune cells, notably T
and B cells, that express highly variable
sets of receptors that mediate a specific
immune response to clear the infection.
The prototypic example of a lymphoid
cell type with innate effector functions
is NK cells, which mediate cytotoxic
activities against target cells that are
‘‘stressed’’ by viral infection or malignant
transformation, providing a first line of
defense against certain viruses and,
potentially, certain tumors. Recent years
have witnessed the emergence of other
innate effector lymphocytes, revealing
a previously unrecognized complexity of
the lymphoid innate immune system.
One such cell type is the well-known
lymphoid tissue inducer (LTi) cell, a key
player in the formation of secondary
lymphoid organs that turned out to have
previously unrecognized effector func-
tions, such as the production of the proin-
flammatory interleukins (IL), IL-17 and
IL-22 (Cupedo et al., 2009). In addition,
novel cell types were recently described
(Cella et al., 2009) (reviewed in Spits and
Di Santo, 2011), some of which share
characteristics with both NK cells andLTi cells and are most likely developmen-
tally related to these two cell types (Spits
and Di Santo, 2011). Interestingly, these
new ILC types can be distinguished
based on cytokine production profiles
and essential transcription factors that
are reminiscent of those found in subpop-
ulations of T helper (Th) cells. Thus, ILC
populations have been found that pro-
duce IL-17 and IL-22 (Cella et al., 2009;
Cupedo et al., 2009) and IL-13 (Moro
et al., 2010) as signature cytokines. Like
Th cells specialized to produce IL-17 and
IL-22, called Th17 cells, ILCs that secrete
these cytokines express and depend on
the transcription factor RORgt. Consistent
with the cytokine profiles of the various
ILC subpopulations are the observations
that certain ILCs are dedicated tomediate
immunity against distinct pathogens. For
instance, IL-13-producing ILCs mediate
immunity against helminths such as
Nippostrongylus brasiliensis (Moro et al.,
2010) and IL-22-producing ILCs mediate
an efficacious IL-22-mediated immune
response against the attaching and
effacing bacterial gut pathogen Citro-
bacter rodentium (Satoh-Takayama
et al., 2008). Confusingly, there is no
consensus regarding the ILC nomencla-
ture. For instance, IL-22-producing ILCs
have been denoted NK22, NCR22, NK-
LTi, and ILC22 cells. Therefore,
a commonly accepted classification of
various ILC populations is badly needed
to avoid further confusion in the field.
IL-22 is a cytokine of special interest. It
is a member of the IL-10 family of cyto-
kines (reviewed in Ouyang et al., 2011)
and is produced by adaptive and innate
immunecells. Its receptor is a heterodimerCell Host & Microof the IL-10R2, which is also part of the
IL-10 receptor complex, and the IL-22R
and is expressed only on nonhemato-
poietic cells (Ouyang et al., 2011). IL-22
activates stromal cells, in particular epi-
thelial cells, to produce chemokines such
as IL-8, which play important roles in
recruiting effector cells like neutrophils
and antibacterial proteins, including
REGIIIb, REGIIIg, and b-defensins that
contribute to protection against patho-
genic microbiota. Although IL-22 can be
produced by many cell types (Ouyang
et al., 2011), several studies, including a
paper in this issue of Cell Host & Microbe
(Tumanov et al., 2011), indicate that ILCs
are the main source of intestinal IL-22
involved in the early immune response
against the pathogenic bacterium
C. rodentium.
Obviously, understanding the signals
triggering RORgt+ ILC effector functions
is required to fully understand the function
of these cells. Previous research has indi-
cated that cytokines are robust stimuli
of ILC effector functions. Most notably,
IL-23 and IL-1b (Hughes et al., 2010), but
also the so-called gc cytokines IL-2,
IL-7, and IL-15 stimulate RORgt+ ILCs to
produce IL-22 (Cella et al., 2009). Also,
Toll-like receptor (TLR) agonists have
been shown to stimulate IL-22-producing
ILCs in vitro, either indirectly by stimu-
lating dendritic cells (DC) and macro-
phages producing IL-23 (Cella et al.,
2009), or directly through TLRs expressed
in ILCs (Crellin et al., 2010). However,
much remains to be learned about how
ILC effector functions are triggered
in vivo. A paper in this issue of Cell Host
& Microbe provides important novelbe 10, July 21, 2011 ª2011 Elsevier Inc. 3
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coworkers report that the lymphotoxin
(LT) pathway plays an essential role in
controlling IL-22 production by RORgt+
ILCs (Tumanov et al., 2011). In a previous
study, this group demonstrated that LTbR
signaling plays a critical role in the de-
fense againstC. rodentium, as LTbR-defi-
cient mice succumb early to infection with
this pathogen (Wang et al., 2010). In view
of earlier reports demonstrating that IL-22
is also essential for protection against
C. rodentium (Zheng et al., 2008), a logical
next step was to investigate the link
between the LTbR and IL-22 pathways.
Indeed, Tumanov et al. report that abol-
ishing LTbR signaling strongly reduces
intestinal IL-22 production induced by
C. rodentium, providing insight into the
mechanism by which the LT pathway
functions in the early immune response
against this pathogen (Tumanov et al.,
2011). LTbR has two major ligands: one
is a membrane-bound heterotrimer, con-
sisting of two LTb molecules and one
LTa molecule (LTa1b2), and the second
ligand is LIGHT, which, like LTa and b, is
a member of the TNF superfamily. Since
LTb/ but not LIGHT/ mice are unable
to produce IL-22 uponC. rodentium infec-
tion, the membrane-bound LTa1b2 trimer
and not LIGHT appears to be the relevant
ligand in this setting. In a subsequent
series of elegant experiments using mice
with cell-specific deletions of LTbR and
LTb, the authors demonstrate that
LTa1b2-expressing RORgt+ ILCs, but not
T and B cells, interact with LTbR+ cells,
mostly CD11c+ DC, to control in vivo
IL-22 production following C. rodentium
infection and thereby resistance to this
pathogen. The demonstration that IL-22
injection prevents lethality in LTb/ mice
convincingly shows that IL-22 down-
stream from LTbR is essential for early re-
sistance to this pathogen. From this study
a picture emerges in which C. rodentium
infection upregulates LTa1b2 expression
in ILCs, which then triggers LTbR+ cells,
mostly CD11c+ DC, to produce cytokines4 Cell Host & Microbe 10, July 21, 2011 ª201that subsequently activate ILCs to pro-
duce effector molecules, most notably
IL-22. The critical cytokine produced by
DC in this setting ismost likely IL-23, since
IL-23/ mice show reduced levels of
IL-22 and thus succumb to C. rodentium
infection (Zheng et al., 2008), although
Tumanov et al. did not show that IL-23
injection rescues C. rodentium-induced
lethality in a setting of LTb deficiency in
RORgt+ ILCs.
This study emphasizes the important
role of LTs in ILC function, which is not
limited to regulating IL-22 production.
LTs are essential for LTi cells to induce
lymph node formation by virtue of their
interaction with LTbR+ stromal cells.
Moreover, LTs play an important role in
the formation of isolated lymphoid follicles
in the gut also through interactions with
LTbR+ stromal cells.
Several questions remain to be ad-
dressed. One is, what stimulates ILCs to
upregulate LTa1b2? One possibility is
that this is triggered by the direct interac-
tion of bacterial antigens, such as TLR
agonists. Another possibility is that bacte-
rial products stimulate certain stromal
cells to produce cytokines such as IL-1b,
IL-7, and IL-15, which together were
shown to strongly stimulate RORgt+
ILCs. LTs that are upregulated as a result
of this stimulation may trigger the
cascade described by Tumanov et al.,
thereby amplifying the IL-22 production
required for resistance against patho-
genic bacteria. Further research should
shed light on the nature of the signals
that trigger the LT pathway.
The results described by Tumanov et al.
raise the interesting question of whether
the LT pathway functions the same way
in humans as in mice. Given the strong
similarity of the ILC systems in mice and
man, this is possibly the case. Therefore,
it is important to determine the effects of
biologicals that interfere with the LT
pathway on gut ILC function. Two drugs
that are designed to disrupt the LT
pathway are currently in clinical develop-1 Elsevier Inc.ment as treatments for immunity-medi-
ated inflammatory diseases such as
Rheumatoid Arthritis. One of these drugs
is the soluble fusion product of the extra-
cellular portion of LTbR and the Fc part
of IgG, called Baminercept, which was
developed by Biogen/IDEC. The other is
an antibody against a homotrimer of
LTa, which also reacts with LTa1b2, that
was developed by Genentech. It will be
interesting to determine whether these
biologicals affect gut immunity.REFERENCES
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